Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67.

Article  CAS  PubMed  Google Scholar 

Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–9.

Article  PubMed  PubMed Central  Google Scholar 

Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–206.

Article  CAS  PubMed  Google Scholar 

Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xin YuJ, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nat Rev Drug Discov. 2019;18(12):899–900.

Article  Google Scholar 

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15(3):426–35.

Article  CAS  PubMed  Google Scholar 

Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.

Article  CAS  PubMed  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020;12:1758835920937612.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.

Article  PubMed  Google Scholar 

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–27.

Article  PubMed  Google Scholar 

Jugder BE, Kamareddine L, Watnick PI. Microbiota-derived acetate activates intestinal innate immunity via the Tip60 histone acetyltransferase complex. Immunity. 2021;54(8):1683-97 e3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492–506.

Article  PubMed  PubMed Central  Google Scholar 

Miyauchi E, Kim SW, Suda W, Kawasumi M, Onawa S, Taguchi-Atarashi N, et al. Gut microorganisms act together to exacerbate inflammation in spinal cords. Nature. 2020;585(7823):102–6.

Article  CAS  PubMed  Google Scholar 

Erny D, Dokalis N, Mezo C, Castoldi A, Mossad O, Staszewski O, et al. Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease. Cell Metab. 2021;33(11):2260-76 e7.

Article  CAS  PubMed  Google Scholar 

Morais LH, Schreiber HLT, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021;19(4):241–55.

Article  CAS  PubMed  Google Scholar 

He Y, Fu L, Li Y, Wang W, Gong M, Zhang J, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 2021;33(5):988-1000 e7.

Article  CAS  PubMed  Google Scholar 

Microbiota-induced IF. I signaling promotes an antitumor microenvironment. Cancer Discov. 2021;11(12):2955.

Article  Google Scholar 

Stower H. Microbiome transplant-induced response to immunotherapy. Nat Med. 2021;27(1):21.

PubMed  Google Scholar 

McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019;20(2):e77–91.

Article  PubMed  Google Scholar 

Fehervari Z. Microbiota shape tumor immunity. Nat Immunol. 2021;22(12):1469.

Article  CAS  PubMed  Google Scholar 

Chen YC, He XL, Qi L, Shi W, Yuan LW, Huang MY, et al. Myricetin inhibits interferon-gamma-induced PD-L1 and IDO1 expression in lung cancer cells. Biochem Pharmacol. 2022;197: 114940.

Article  CAS  PubMed  Google Scholar 

Hu Q, Jiang L, Yan Q, Zeng J, Ma X, Zhao Y. A natural products solution to diabetic nephropathy therapy. Pharmacol Ther. 2023;241: 108314.

Article  CAS  PubMed  Google Scholar 

Duan S, Zhang M, Zeng H, Song J, Zhang M, Gao S, et al. Integrated proteomics and phosphoproteomics profiling reveals the cardioprotective mechanism of bioactive compounds derived from Salvia miltiorrhiza Burge. Phytomedicine. 2023;117: 154897.

Article  CAS  PubMed  Google Scholar 

Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, et al. The gut microbiome is associated with clinical response to Anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8(10):1251–61.

Article  PubMed  Google Scholar 

Fenton TM, Jorgensen PB, Niss K, Rubin SJS, Morbe UM, Riis LB, et al. Immune profiling of human gut-associated lymphoid tissue identifies a role for isolated lymphoid follicles in priming of region-specific immunity. Immunity. 2020;52(3):557-70 e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin XL, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31(5):781-97 e9.

Article  CAS  PubMed  Google Scholar 

Park JS, Gazzaniga FS, Wu M, Luthens AK, Gillis J, Zheng W, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023;617(7960):377–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.

Article  CAS  PubMed  Google Scholar 

Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacter